| scholarly article | Q13442814 |
| P2093 | author name string | Prins JM | |
| Speelman P | |||
| Weverling GJ | |||
| van Ketel RJ | |||
| de Blok K | |||
| P2860 | cites work | Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients | Q28367851 |
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982 | Q34055509 | ||
| Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin | Q34056699 | ||
| Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring | Q34061646 | ||
| Determinants of efficacy and toxicity of aminoglycosides | Q34510814 | ||
| Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations | Q35674282 | ||
| A critical reevaluation of the "therapeutic range" of aminoglycosides | Q36043679 | ||
| Gentamicin serum concentrations: pharmacokinetic predictions | Q39218883 | ||
| Once versus thrice daily gentamicin in patients with serious infections | Q39369365 | ||
| Experience with a once-daily aminoglycoside program administered to 2,184 adult patients | Q39779327 | ||
| Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients | Q40718971 | ||
| Single or multiple daily doses of aminoglycosides: a meta-analysis | Q42145555 | ||
| Incidence of amikacin ototoxicity: a sigmoid function of total drug exposure independent of plasma levels | Q42198825 | ||
| Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination | Q42286407 | ||
| Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone | Q43459102 | ||
| Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model | Q43617611 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Furosemide Enhancement of Experimental Gentamicin Nephrotoxicity: Comparison of Functional and Morphological Changes with Activities of Urinary Enzymes | Q46036624 | ||
| Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. Scandinavian Amikacin Once Daily Study Group. | Q50529699 | ||
| The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. | Q52695343 | ||
| Easier monitoring of aminoglycoside therapy with once-daily dosing schedules | Q59688603 | ||
| Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections | Q68509565 | ||
| A model for predicting nephrotoxicity in patients treated with aminoglycosides | Q69493303 | ||
| Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage | Q69589550 | ||
| Furosemide accelerates gentamicin accumulation in cultured renal cells (LLC-PK1 cells) | Q69792977 | ||
| Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia | Q70386358 | ||
| Gentamicin dosing errors with four commonly used nomograms | Q70432512 | ||
| Monitoring serum concentrations for once-daily netilmicin dosing regimens | Q72417285 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2494-2499 | |
| P577 | publication date | 1996-11-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy | |
| P478 | volume | 40 |
| Q38090988 | Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk |
| Q33605648 | Aminoglycosides: nephrotoxicity |
| Q37246422 | Atorvastatin for Prevention of Amikacin-induced Electrolytes Imbalances; a Randomized Clinical Trial |
| Q59329485 | Ceftriaxone treatment of complicated urinary tract infections as a risk factor for enterococcal re-infection and prolonged hospitalization: A 6-year retrospective study |
| Q73562544 | Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients |
| Q33882620 | Clinical pharmacokinetics and pharmacodynamics of isepamicin |
| Q42209082 | Development and validation of a novel vancomycin dosing nomogram for achieving high-target trough levels at 2 canadian teaching hospitals |
| Q33645586 | Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring |
| Q34894900 | How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? |
| Q34458340 | Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? |
| Q28194278 | Limited predictability of amikacin clearance in extreme premature neonates at birth |
| Q34139570 | New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. |
| Q33545113 | Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? |
| Q35738386 | Once-daily aminoglycoside dosing: An update on current literature |
| Q33928699 | Once-daily dosing of aminoglycoside antibiotics |
| Q34549036 | Pediatric Risk, Injury, Failure, Loss, End-Stage renal disease score identifies acute kidney injury and predicts mortality in critically ill children: a prospective study |
| Q37247721 | Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units |
| Q44996391 | Protective effect of aminoguanidine against nephrotoxicity induced by amikacin in rats. |
| Q35826231 | Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. |
| Q36076732 | Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis |
| Q33751736 | Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study |
| Q34752229 | Risk factors for toxicity in elderly patients given aminoglycosides once daily. |
| Q36333140 | The 6R's of drug induced nephrotoxicity |
| Q40668918 | The effectiveness and safety of two prophylactic antibiotic regimes in hip-fracture surgery. |
| Q42021204 | The role of MAPK in drug-induced kidney injury. |
Search more.